NIH Rejects Compulsory License For Abbott's Norvir

Law360, New York (August 5, 2004, 12:00 AM EDT) -- A U.S. government agency has rejected calls for a compulsory license for a popular HIV medicine used to boost AIDS drugs, dealing a setback for activists who had hoped to use a little-known law to override a drug maker’s patent rights.

In its ruling, the National Institutes of Health rejected a "march-in petition" filed by Essential Inventions, which urged the NIH to claim control over patent rights to Norvir, a drug sold by Abbott Laboratories. The group asked the NIH to act after Abbott raised the...
To view the full article, register now.